Ep190: Neil Kumar on Building a Rare Disease Drug Company
The Long Run with Luke Timmerman
00:00
Early fundraising and first investors
Neil recalls the difficult reception, the first $7 million from high-net-worth backers, and scrapping the MATLAB pitch.
Play episode from 26:42
Transcript
